Piflufolastat F 18

Generic Name
Piflufolastat F 18
Brand Names
Pylarify, Pylclari
Drug Type
Small Molecule
Chemical Formula
C18H23FN4O8
CAS Number
1207181-29-0
Unique Ingredient Identifier
3934EF02T7
Background

Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases and recurrences. The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but...

Indication

Piflufolastat F18 is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer who have suspected metastases and are candidates for initial definitive therapy and for men with a suspected recurrence of prostate cancer based on elevated prostate-specific antigen (PSA) levels by t...

Associated Conditions
Prostate Cancer, Recurrent Prostate Cancer
Associated Therapies
-
Clinical Trials
Related News

Integrated 18F-labelled PSMA Project

Early Phase 1
Conditions
Prostate Cancer
Interventions
Drug: 18F-DCFPyL
First Posted Date
2016-02-25
Last Posted Date
2017-10-09
Lead Sponsor
St. Joseph's Healthcare Hamilton
Target Recruit Count
10
Registration Number
NCT02691169
Locations
🇨🇦

St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada

Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

Not Applicable
Completed
Conditions
Renal Cell Carcinoma
Kidney Cancer
Interventions
Drug: 18F-DCFPyL
Procedure: PET/CT
First Posted Date
2016-02-22
Last Posted Date
2020-04-29
Lead Sponsor
Johns Hopkins University
Target Recruit Count
34
Registration Number
NCT02687139
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

Not Applicable
Completed
Conditions
Adenocarcinoma of the Prostate
Interventions
Drug: 18F-DCFPyL
First Posted Date
2015-08-14
Last Posted Date
2020-01-31
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
50
Registration Number
NCT02523924
Locations
🇺🇸

SKCCC, Baltimore, Maryland, United States

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

Phase 1
Completed
Conditions
Metastatic Prostate Cancer
Interventions
Drug: 18F-DCFPyL
First Posted Date
2014-05-30
Last Posted Date
2020-05-07
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
37
Registration Number
NCT02151760
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy